Reviewing Big Cypress Acquisition (OTCMKTS:BCYP) & Amgen (NASDAQ:AMGN)

Big Cypress Acquisition (OTCMKTS:BCYP) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Big Cypress Acquisition and Amgen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Big Cypress Acquisition	N/A	N/A	N/A
Amgen	13.00%	168.35%	11.18%

Valuation and Earnings

This table compares Big Cypress Acquisition and Amgen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A
Amgen	$32.53 billion	4.41	$6.72 billion	$7.81	34.20

Amgen has higher revenue and earnings than Big Cypress Acquisition.

Analyst Ratings

This is a summary of current recommendations and price targets for Big Cypress Acquisition and Amgen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Big Cypress Acquisition	0	0	0	0	0.00
Amgen	2	12	12	1	2.44

Amgen has a consensus target price of $314.91, suggesting a potential upside of 17.90%. Given Amgen’s stronger consensus rating and higher probable upside, analysts plainly believe Amgen is more favorable than Big Cypress Acquisition.

Summary

Amgen beats Big Cypress Acquisition on 11 of the 11 factors compared between the two stocks.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.